Skip to content
10-Q

Quarterly Report

Aclaris Therapeutics, Inc. ACRS

0001558370-25-006993

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 30, 2025 108.28M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $30.36M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $24.57M
Current Liabilities Q1 2025 · Mar 31, 2025 $21.51M
Current Liabilities Q1 2025 · Dec 31, 2024 $31.6M
Total Liabilities Q1 2025 · Mar 31, 2025 $54.03M
Total Liabilities Q1 2025 · Dec 31, 2024 $64.77M
Current Assets Q1 2025 · Mar 31, 2025 $108.79M
Current Assets Q1 2025 · Dec 31, 2024 $125.95M
Total Assets Q1 2025 · Mar 31, 2025 $198.09M
Total Assets Q1 2025 · Dec 31, 2024 $220.33M
Shares Diluted Q1 2025 · Mar 31, 2024 71.07M sh
Capex Q1 2025 · Mar 31, 2024 $135K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$20.82M
Stockholders Equity Q1 2025 · Mar 31, 2024 $142.01M
Stockholders Equity Q1 2025 · Dec 31, 2023 $157.18M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.24
Eps Basic Q1 2025 · Mar 31, 2024 −$0.24
Sga Expense Q1 2025 · Mar 31, 2024 $6.84M
Rd Expense Q1 2025 · Mar 31, 2024 $9.85M
Net Income Q1 2025 · Mar 31, 2024 −$16.94M
Operating Income Q1 2025 · Mar 31, 2024 −$18.93M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $809K
Revenue Q1 2025 · Mar 31, 2024 $2.4M